Has Lazertinib been included in the national medical insurance reimbursement catalog?

As of now, Lazertinib (Lazertinib) has not been included in China’s national medical insurance reimbursement catalog. Although the drug has been approved by the China National Medical Products Administration for the treatment of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, due to its short time on the market, it has not yet entered into medical insurance negotiations or centralized procurement processes, so patients still need to pay for the drug at their own expense.

Lanzatinib is a third-generation EGFRtyrosine kinase inhibitor (TKI), mainly used to treat first- or second-generation pan>EGFR-TKIresistantT790Mmutation-positiveNSCLC patients. In clinical studies, lanzetinib has shown good tumor response rates and long progression-free survival, especially in patients with brain metastases, and has attracted much attention from doctors and patients.

In terms of price, the original drug of Lanzertinib is not yet widely available in China, but according to quotations in foreign markets, the price of a box of 84 capsules of 80mg is approximately RMB 60,000. Since it is not covered by medical insurance, patients need to bear the cost themselves, which is a large financial burden for many families. Therefore, some patients may choose to purchase foreign versions through formal channels or look for generic drugs, but such use must be under the guidance of a doctor.

In the future, with the accumulation of more clinical data and recognition of the drug's efficacy, lanzitinib is expected to enter the national medical insurance negotiation catalog. Once included in medical insurance, patients will greatly reduce their financial burden and the threshold for use will also be lowered. It is recommended that patients consult their attending physician before taking medication and pay attention to the latest drug catalog adjustment policy issued by the National Medical Insurance Administration.

Reference materials:https://www.drugs.com/donanemab.html